

# CONTENTS

---

Dedication .....	v
Preface .....	vii
Contributors .....	xi

## **PART I: BIOCHEMISTRY, PHARMACOLOGY, AND CHEMISTRY**

1	Mechanism of Action of Topoisomerase 1 Poisons .....	3
	<i>Leroy F. Liu and Shyamal D. Desai</i>	
2	Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage .....	23
	<i>Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart</i>	
3	Inhibitors of Topoisomerase I Function .....	39
	<i>Sidney M. Hecht</i>	
4	Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors .....	61
	<i>Yves G. Pommier, Juana Barceló, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao</i>	
5	Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage .....	109
	<i>Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti</i>	
6	Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs .....	127
	<i>Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton</i>	
7	Mechanisms of Resistance to Camptothecins .....	153
	<i>Zeshaan A. Rasheed and Eric H. Rubin</i>	
8	Recent Advances in Camptothecin Drug Design and Delivery Strategies .....	171
	<i>Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus</i>	

## **PART II: CLINICAL PERSPECTIVES**

9	Clinical Experience With 9-Aminocamptothecin: <i>Lessons for New Drug Development</i> .....	193
	<i>Chris H. Takimoto</i>	

10	Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) .....	207
	<i>Hilary Hewes, Judith A. Smith, and Claire Verschraegen</i>	
11	Irinotecan: <i>Current Clinical Status and Pharmacological Aspects</i> .....	229
	<i>Laurent P. Rivory</i>	
12	Clinical Experience With Topotecan .....	263
	<i>Aimee K. Bence and Val R. Adams</i>	
13	The Clinical Development of Lurtotecan: <i>Experience With Water-Soluble and Liposomal Forms</i> .....	301
	<i>Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer</i>	
14	Preclinical and Clinical Development of Exatecan (DX-8951f): <i>A Hexacyclic Camptothecin Analog</i> .....	317
	<i>Eric K. Rowinsky</i>	
15	Camptothecins in the Treatment of Primary Brain Tumors .....	343
	<i>Clinton F. Stewart, Markos Leggas, and Henry S. Friedman</i>	
16	Camptothecins in the Treatment of Lung Cancer .....	369
	<i>Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler</i>	
17	Use of Camptothecins in the Treatment of Leukemia and Related Disorders .....	421
	<i>Benjamin M. F. Mow and Scott H. Kaufmann</i>	
	Index .....	451



<http://www.springer.com/978-1-58829-027-4>

Camptothecins in Cancer Therapy

Adams, V.R. (Ed.)

2005, XIII, 460 p., Hardcover

ISBN: 978-1-58829-027-4

A product of Humana Press